Torres Marcelo D T, Wan Fangping, de la Fuente-Nunez Cesar
Machine Biology Group, Departments of Psychiatry and Microbiology, Institute for Biomedical Informatics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Departments of Bioengineering and Chemical and Biomolecular Engineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
bioRxiv. 2024 Nov 16:2024.11.15.623859. doi: 10.1101/2024.11.15.623859.
Antimicrobial resistance (AMR) is one of the greatest threats facing humanity, making the need for new antibiotics more critical than ever. While most antibiotics have traditionally been derived from bacteria and fungi, archaea-a distinct and underexplored domain of life-offer a largely untapped reservoir for antibiotic discovery. In this study, we leveraged deep learning to systematically explore the archaeome, uncovering promising new candidates for combating AMR. By mining 233 archaeal proteomes, we identified 12,623 molecules with potential antimicrobial activity. These newly discovered peptide compounds, termed archaeasins, exhibit unique compositional features that differentiate them from traditional antimicrobial peptides, including a distinct amino acid profile. We synthesized 80 archaeasins, 93% of which demonstrated antimicrobial activity . Notably, validation identified archaeasin-73 as a lead candidate, significantly reducing bacterial loads in mouse infection models, with effectiveness comparable to established antibiotics like polymyxin B. Our findings highlight the immense potential of archaea as a resource for developing next-generation antibiotics.
抗菌耐药性(AMR)是人类面临的最大威胁之一,这使得对新型抗生素的需求比以往任何时候都更加迫切。虽然大多数抗生素传统上来源于细菌和真菌,但古菌——一个独特且未被充分探索的生命领域——为抗生素发现提供了一个很大程度上未被开发的资源库。在这项研究中,我们利用深度学习系统地探索古菌基因组,发现了对抗抗菌耐药性有前景的新候选物。通过挖掘233个古菌蛋白质组,我们鉴定出12623种具有潜在抗菌活性的分子。这些新发现的肽化合物,称为古菌素,表现出独特的组成特征,使它们与传统抗菌肽不同,包括独特的氨基酸谱。我们合成了80种古菌素,其中93%表现出抗菌活性。值得注意的是,验证确定古菌素-73为主要候选物,在小鼠感染模型中显著降低细菌载量,其有效性与多粘菌素B等已确立的抗生素相当。我们的研究结果突出了古菌作为开发下一代抗生素资源的巨大潜力。